Brokerage firm Roth Capital Upgrades its rating on Aptose Biosciences Inc(NASDAQ:APTO). In a research note issued to the investors, the brokerage major Raises the price-target to $8.00 per share. The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by Roth Capital was issued on Jun 13, 2016.
Aptose Biosciences Inc(APTO) last announced its earnings results on May 10, 2016 for Fiscal Year 2016 and Q1.Earnings per share were $-0.32. Analysts had estimated an EPS of $-0.37.
Aptose Biosciences Inc. (Aptose) is a clinical stage biotechnology company. The Company is engaged in development of targeted therapies addressing unmet medical needs in oncology. The Company has product candidates in two classes of anti-cancer therapies: Small molecule program and large molecule program. The Company’s group of small molecule compounds includes lead drug APTO-253 in acute myeloid leukemia (AML) myelodysplastic syndromes (MDS) and other hematologic malignancies. APTO-253 is an inducer of the Kruppel-like factor 4 gene (the Klf4 Gene) for patients with advanced hematologic malignancies. Additionally the Company has a preclinical small molecule program APTO-500 targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of various cancers. The Company’s large molecule program includes a molecule to target specific cell-surface receptors expressed in certain cancers expressing the Interleukin-17E receptor (IL-17ER).